Publications by authors named "Michael Troner"
Article Synopsis
- The text outlines updated evidence-based guidelines from ASCO regarding platelet transfusion practices for cancer patients, replacing guidelines from 2001.
- The update involved a systematic review of literature from 2014 to 2016, including insights from other organizations like AABB, focusing on areas not fully covered previously.
- Major changes include allowing adult patients undergoing autologous stem-cell transplantation to receive transfusions at the first sign of bleeding instead of preemptively, while maintaining prophylactic transfusions for certain pediatric and allogeneic patients.
Background: Our aim was to determine whether percutaneous endoscopic gastrostomy (PEG) dependence was significantly different between 2 prospective trials with different radiation fractionation schemes.
Methods: Stage III or IV locally advanced head and neck squamous cell carcinomas arising from the oral cavity, hypopharynx, oropharynx, nasopharynx, paranasal sinuses, or larynx were treated using hyperfractionation (A-3 protocol) or accelerated fractionation (A-4 protocol) with chemotherapy. Amifostine was administered 15 to 30 minutes preradiation, at a dose of 500 mg/day in both protocols.
The objective of this study was to determine the toxicity and efficacy of the current phase II chemoradiation protocol. Stage III or IV locally advanced head and neck squamous cell carcinomas arising from the oral cavity, hypopharynx, oropharynx, nasopharynx, paranasal sinuses, or larynx were treated using hyperfractionated radiation (74.4 Gy at twice-daily fractions of 1.
View Article and Find Full Text PDFPurpose: To determine quality of life (QOL) after hyperfractionated radiation and chemotherapy.
Materials And Methods: Functional Assessment of Cancer Therapy (FACT) and the Functional Assessment of Cancer Therapy-Head and Neck (FACT H-N) questionnaires were administered to protocol patients at baseline study entry, during and at the completion of therapy, and during subsequent follow-up.
Results: Twenty-four patients completed baseline QOL questionnaires.
Purpose: To determine the toxicity and efficacy of concurrent 5-fluorouracil (5-FU), cisplatin, and paclitaxel (Taxol) and hyperfractionated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
Methods And Materials: Twenty-seven patients were entered into this Phase II trial. Eligible patients had Stage III or IV head-and-neck squamous cell carcinoma arising from the oral cavity, hypopharynx, oropharynx, nasopharynx, or larynx.